Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with ...

Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclibOPERA-01 trial-in-progress poster to be presented on Monday, June 2 between ...

Parexel also launching a comprehensive Radiopharmaceuticals report at the meeting Onsite Parexel experts include recently appointed Chief Medical Officer and veteran oncologist Dr. Charlotte Moser, ...

This update will be presented as part of the OPERA-01 trial-in-progress poster at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago, Illinois.

FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global ...

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today unveiled its upcoming contributions ...

through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.

Research shows ability to surface real-world, regimen-specific symptom trends and highlight potential in-class differences using the Canopy Remote ...

Onc.AI’s poster presentation showcases its FDA-breakthrough ... conventional criteria would signal poor prognosis. At the ASCO Innovation Hub (IH13), Onc.AI will share latest results from ...